Blood Res.  2016 Dec;51(4):217-219. 10.5045/br.2016.51.4.217.

Copper deficiency mimicking myelodysplastic syndrome

• D'Angelo G

• KMID: 2364308
• DOI: http://doi.org/10.5045/br.2016.51.4.217

Abstract

No abstract available.

MeSH Terms

Copper*
Myelodysplastic Syndromes*
Copper

Figure

• 

  Fig. 1 The iron and copper transport pathways and their interactions. Into the enterocytes, dietary iron and copper are absorbed by DMT1 and CTR1, repectively, after reduction. Iron and copper are exported from enterocyte by ferroportin and ATP7A, respectively. Copper deficiency decreases the quantity of HP which is required for efficient enterocyte iron efflux and loading onto TF. CP carries 70–95% of the total copper in plasma. Hepatocytes can take up Fe-TF by TFR. Copper taken up by hepatocyte CTR1 is delivered to ATP7B and CP. CP facilitates iron loading onto TF by oxidation (Fe2+→Fe3+). Hepatocytes control iron metabolism by producing the hepcidin which inhibits iron export. Fe-TF is transported to the marrow and utilized for the erythropoietic activity. Iron taken up by erythrocyte, the major iron consumer, is transferred to the mitochondria together with copper, and used for heme systhesis. Copper deficiency can impair the uptake of iron by mitochondria and cause decrease of heme synthesis. Macrophage phagocytoses senescent RBC and the irons are utilized or stored in ferritin.Abbreviations: ATP7A, ATPase Cu2+ transporting alpha polypeptide; ATP7B, ATPase Cu2+ transporting beta polypeptide; CP, ceruloplasmin; CTR1, copper transporter 1; DMT1, divalent metal transporter 1; Hb, hemoglobin; HP, hephaestin; GPI, glycosylphosphatidylinositol; RBC, red blood cell; TF, transferrin; TFR, transferrin receptor.

Reference

1. Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol. 2008; 80:523–531. PMID: 18284630.

2. Collins JF, Prohaska JR, Knutson MD. Medtabolic crossroads of iron and copper. Nutr Rev. 2010; 68:133–147. PMID: 20384844.

3. Klevay LM. “Myelodysplasia,” myeloneuropathy, and copper deficiency. Mayo Clin Proc. 2006; 81:132.

4. Green R. Anemias beyond B12 and iron deficiency: the buzz about other B's, elementary, and nonelementary problems. Hematology Am Soc Hematol Educ Program. 2012; 2012:492–498. PMID: 23233624.

5. Lazarchick J. Update on anemia and neutropenia in copper deficiency. Curr Opin Hematol. 2012; 19:58–60. PMID: 22080848.

6. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002; 100:1493–1495. PMID: 12149237.

7. Simon SR, Branda RF, Tindle BF, Burns SL. Copper deficiency and sideroblastic anemia associated with zinc ingestion. Am J Hematol. 1988; 28:181–183. PMID: 3407636.

8. D'Angelo G. Plasma cell and iron granules. Haematologica. 1996; 81:588. PMID: 9009447.

9. Sutton L, Vusirikala M, Chen W. Hematogone hyperplasia in copper deficiency. Am J Clin Pathol. 2009; 132:191–199. PMID: 19605813.

10. Font P, Loscertales J, Benavente C, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013; 92:19–24. PMID: 22948274.